Anticoagulation Strategies in Patients With Cancer : JACC Review Topic of the Week

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..

Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer.

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:73

Enthalten in:

Journal of the American College of Cardiology - 73(2019), 11 vom: 26. März, Seite 1336-1349

Sprache:

Englisch

Beteiligte Personen:

Mosarla, Ramya C [VerfasserIn]
Vaduganathan, Muthiah [VerfasserIn]
Qamar, Arman [VerfasserIn]
Moslehi, Javid [VerfasserIn]
Piazza, Gregory [VerfasserIn]
Giugliano, Robert P [VerfasserIn]

Links:

Volltext

Themen:

Anticoagulants
Anticoagulation
Atrial fibrillation
Bleeding
Cancer
Cardio-oncology
Journal Article
Research Support, N.I.H., Extramural
Review
Venous thromboembolism

Anmerkungen:

Date Completed 27.02.2020

Date Revised 19.09.2023

published: Print

Citation Status MEDLINE

doi:

10.1016/j.jacc.2019.01.017

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM295208260